Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Glenza 40mg Tablets | 112-Count | ENZALUTAMIDE
Pharma

Glenza 40mg Tablets | 112-Count | ENZALUTAMIDE

$290

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

India Warehouse ENZALUTAMIDE — 40mg per tablet, 112-count pack. Androgen receptor inhibitor for castration-resistant prostate cancer (CRPC) — both non-metastatic and metastatic, and metastatic castration-sensitive prostate cancer (mCSPC). Key warning: Seizure risk — avoid in patients with history of seizures. Falls and fractures — bone protection. CYP3A4 and CYP2C8 inducer — reduces levels of many medications. Embryofetal toxicity.

SKU
VES-008774-GLENZA-40MG-112TAB
Format
N/A
Use
Laboratory research only
Ask on Telegram

What is Glenza 40mg (1X14) (ENZALUTAMIDE)?

Androgen receptor inhibitor for castration-resistant prostate cancer (CRPC) — both non-metastatic and metastatic, and metastatic castration-sensitive prostate cancer (mCSPC).

How it Works

Blocks androgen receptor (AR) signaling at multiple steps: prevents androgen binding, AR nuclear translocation, and AR-DNA interaction. More potent than first-generation anti-androgens.

Quick Specs

Form
Oral tablets — pre-dosed
Active Ingredient
ENZALUTAMIDE
Dose per Tablet
40MG
Pack Size
112 tablets
Storage
Room temperature (15–25°C), cool dry place
Shelf Life
2–3 years (properly stored)

Common Side Effects

Fatigue (most common), hot flushes, hypertension, seizures (<1% risk), fall/fractures, cognitive effects, QT prolongation.

Safety Warnings

Seizure risk — avoid in patients with history of seizures. Falls and fractures — bone protection. CYP3A4 and CYP2C8 inducer — reduces levels of many medications. Embryofetal toxicity. International shipping: 7–14 days

Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.